Aquestive Therapeutics Shares Owned By Institutions vs. Net Income
| AQST Stock | USD 3.61 0.08 2.17% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.73 | 0.5882 |
|
|
For Aquestive Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Aquestive Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Aquestive Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Aquestive Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Aquestive Therapeutics over time as well as its relative position and ranking within its peers.
Aquestive |
Aquestive Therapeutics' Revenue Breakdown by Earning Segment
Check out Trending Equities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aquestive Therapeutics. If investors know Aquestive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aquestive Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Revenue Per Share 0.73 | Quarterly Revenue Growth 0.042 | Return On Assets (0.16) |
The market value of Aquestive Therapeutics is measured differently than its book value, which is the value of Aquestive that is recorded on the company's balance sheet. Investors also form their own opinion of Aquestive Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aquestive Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aquestive Therapeutics' market value can be influenced by many factors that don't directly affect Aquestive Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aquestive Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aquestive Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aquestive Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Aquestive Therapeutics Net Income vs. Shares Owned By Institutions Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Aquestive Therapeutics's current stock value. Our valuation model uses many indicators to compare Aquestive Therapeutics value to that of its competitors to determine the firm's financial worth. Aquestive Therapeutics is rated below average in shares owned by institutions category among its peers. It is rated fifth in net income category among its peers . At this time, Aquestive Therapeutics' Net Loss is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Aquestive Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Aquestive Net Income vs. Shares Owned By Institutions
Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
Aquestive Therapeutics |
| = | 56.03 % |
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Aquestive Therapeutics |
| = | (7.87 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Aquestive Net Income Comparison
Aquestive Therapeutics is currently under evaluation in net income category among its peers.
Aquestive Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Aquestive Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Aquestive Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Aquestive Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Aquestive Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -34.2 M | -36 M | |
| Operating Income | -15.1 M | -15.9 M | |
| Net Loss | -7.9 M | -8.3 M | |
| Income Before Tax | -7.6 M | -8 M | |
| Total Other Income Expense Net | 7.5 M | 7.9 M | |
| Net Loss | -49 M | -51.4 M | |
| Net Loss | -7.9 M | -8.3 M | |
| Income Tax Expense | 245 K | 232.8 K | |
| Interest Income | 16.3 M | 17.1 M | |
| Net Interest Income | 8.9 M | 9.3 M | |
| Non Operating Income Net Other | -12.1 M | -11.5 M | |
| Change To Netincome | 23.4 M | 11.8 M | |
| Net Loss | (0.13) | (0.13) | |
| Income Quality | 0.81 | 0.85 | |
| Net Income Per E B T | 1.03 | 1.25 |
Aquestive Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Aquestive Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Aquestive Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Aquestive Therapeutics' important profitability drivers and their relationship over time.
Use Aquestive Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aquestive Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aquestive Therapeutics will appreciate offsetting losses from the drop in the long position's value.Aquestive Therapeutics Pair Trading
Aquestive Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Aquestive Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aquestive Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aquestive Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aquestive Therapeutics to buy it.
The correlation of Aquestive Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aquestive Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aquestive Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aquestive Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Aquestive Therapeutics position
In addition to having Aquestive Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Gambling Thematic Idea Now
Gambling
Companies that are related to providing gambling services across multiple geographical areas by investing, exploring, or producing software, hardware, and related infrastructure for running gambling operations or trading speculative assets. The Gambling theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Gambling Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Aquestive Stock Analysis
When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.